TNF and rheumatoid arthritis: Although strong preclinical rationale supports IL-17 as a therapeutic target in RA, clinical trials provide mixed data; some demonstrate efficacy in biologic-naïve patients or those unresponsive to TNF inhibitors, whereas others indicate limited therapeutic impact, suggesting that IL-17 is not the sole pathological mediator in RA inflammation [225].